Chūgai Seiyaku

from Wikipedia, the free encyclopedia
Chūgai Seiyaku

logo
legal form KK
ISIN JP3519400000
founding 1925
Seat Tokyo Prefecture , JapanJapanJapan 
management Osamu Nagayama
Number of employees 6,872
sales 423.7 billion yen ($ 3.38 billion)
Branch Pharma
Website www.chugai-pharm.co.jp
Stand 2013

Chūgai Seiyaku Kabushiki kaisha ( Japanese 中外 製 薬 株式会社 ; English Chugai Pharmaceutical Co., Ltd. ) is a Japanese pharmaceutical company founded in Tokyo in 1925 . It is listed on the Nikkei 225 . The registered office is Kita , the actual Chūō .

The company has been active on the German market in the fields of hematology and oncology since 1998 . The best-known products are Epogin ( Erythropoietin ) and Granocyte ( G-CSF ), in 2010 the company also took over the distribution of Capecitabine (Xeloda®). In 2002, Chugai merged with Roche Nippon , making it the fifth largest pharmaceutical company in Japan. In June 2014 Roche held a stake of around 62%.

history

  • 1925: Juzo Oeno founded Chugai Shinyaku Co. Ltd. and started importing and selling medicines.
  • 1927: Start of the first own production.
  • 1930: Salobrocanon , an analgesic (pain reliever ) and antipyretic, is launched.
  • 1937: start of the production of calcium bromide.
  • 1943: Name changed to Chugai Pharmaceutical Ltd. based in Tokyo .
  • 1944: Acquisition of Matsunaga Pharmaceutical Ltd. and construction of a plant in Matsunaga .
  • 1945: The headquarters, the factories in Ikebukuro, Sakai and Takada were destroyed in World War II, the headquarters were relocated to Takada, the factory in Takada was rebuilt.
  • 1946: Construction of the plant in Kamagiishi.
  • 1951: Guronsan , a drug to detoxify and restore liver function, is launched.
  • 1952: Varsan , a perspiration insecticide , is launched.
  • 1955: Chugai became a public company .
  • 1956: The stock is listed on the Tokyo Stock Exchange .
  • 1957: Construction of the Ukima plant.
  • 1960: Establishment of a research center (Takada Research Laboratory, Tokyo).
  • 1967: Foundation of Fukushima Kasai Co Ltd.
  • 1969: The name of Fukushima Kasai Co Ltd. is changed to Eiko Kasei Co Ltd . , after the merger of Fukushima Kasai Co Ltd. and Fukuma Kasau Co. Ltd.
  • 1971: Construction of the factory in Fujieda.
  • 1975: Picibanil , a cancer drug, is launched.
  • 1982: Opening of a branch in New York .
  • 1986: Opening of a branch in London .
  • 1989: Acquisition of Gen-Probe Incorporated (USA).
  • 1990: Epogin launched.
  • 2002: Start of the alliance with Roche .
  • 2003: Xeloda , a cancer drug, is launched.
  • 2005: Actembra launched .
  • 2007: Copegus , an antiviral, Avastin , a cancer drug, and Tarceva , a cancer drug launched.
  • 2014: Launch of Cadcyla , a cancer drug, Chugai Pharma China Co Ltd. founded
  • 2016: Cooperation between Osaka University and Chugai.
  • 2018: Tecentriq , a cancer drug, is launched.

Web links

Individual evidence

  1. ↑ a b Annual Report 2013 ( Memento of the original dated February 10, 2015 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. @1@ 2Template: Webachiv / IABot / www.chugai-pharm.co.jp
  2. ^ International Directory of Company Histories . St. James Press, 2002, ISBN 978-1-55862-476-4 ( books.google.de ).
  3. ↑ bloomberg.com: Roche Said to Have Decided Against Bid for Rest of Chugai - Bloomberg , accessed on February 16, 2017
  4. ↑ history. www. chugai-pharm.co.jp, accessed June 18, 2019 .